NVAX Novavax Inc

By Kathryn Hardison

Novavax Inc. has received emergency use authorization from the U.S. Food and Drug Administration for its protein-based Covid-19 booster for adults.

The vaccine has been approved as a first booster dose for people of at least 18 years of age who received a primary Covid-19 vaccination at least six months prior, the biotechnology company said Wednesday.

The booster is authorized for adults without access to an FDA-authorized mRNA bivalent booster vaccine and for adults who would otherwise not receive a booster, the company said.

The next step is a policy recommendation for use as a first booster from the Centers for Disease Control and Prevention, Novavax said.

The vaccine also is available for use as a booster in adults aged 18 and older in the European Union, Japan, Australia, New Zealand, Switzerland and Israel.

Write to Kathryn Hardison at kathryn.hardison@wsj.com

(END) Dow Jones Newswires

October 19, 2022 11:40 ET (15:40 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.